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Optimizing glycerosome formulations via an orthogonal 
experimental design to enhance transdermal triptolide delivery
Triptolide exerts strong anti-inflammatory and immuno-
modulatory effects; however, its oral administration might 
be associated with side effects. Transdermal administration 
can improve the safety of triptolide. In this study, glycero-
somes were prepared as the transdermal vehicle to enhance 
the transdermal delivery of triptolide. With entrapment 
 efficiency and drug loading as dependent variables, the 
glycerosome formulation was optimized using an ortho-
gonal experimental design. Phospholipid-to-cholesterol 
and phospholipid-to-triptolide mass ratios of 30:1 and 5:1, 
respectively and a glycerol concentration of 20 % (V/V) were 
used in the optimization. The glycerosomes prepared with 
the optimized formulation showed good stability, with an 
average particle size of 153.10 ± 2.69 nm, a zeta potential of 
–45.73 ± 0.60 mV and an entrapment greater than 75 %. 
Glycerosomes significantly increased the transdermal 
 delivery of triptolide compared to conventional liposomes. 
As efficient carriers for the transdermal delivery of drugs, 
glycerosomes can potentially be used as an alternative to 
oral triptolide administration.
Keywords: nanocarriers, liposomes, glycerosomes, trans-
dermal, rheumatoid arthritis
Triptolide (Fig. 1) is an active pharmaceutical ingredient extracted from the herb 
Tripterygium wilfordii. The compound has a melting point of 226–227 °C and it is poorly 
soluble in water with the apparent solubility in the pure water of 21.38 ± 0.36 μg mL–1. Its 
apparent oil-water partition coefficient in the n-octanol/water system is 0.60 (log P) (1). The 
acidity of triptolide is very weak and the degree of ionization is very small. It shows 
 exceptional therapeutic effects against various immune and inflammatory diseases and is 
used in the treatment of rheumatoid arthritis (2, 3). However, oral administration of 
 triptolide irritates the gastrointestinal tract and exerts liver toxicity (4, 5). Transdermal 
administration can reduce side effects and associated toxicity and avoid their first-pass 
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Liposomes are commonly used drug carriers for transdermal delivery. Owing to their 
low deformability, conventional liposomes have poor penetration into the stratum corneum 
and are generally administered locally for the treatment of skin diseases. To enhance the 
transdermal permeability of liposomes, some low-chain alcohols are used as edge activa-
tors to improve the deformability of liposome vesicles (7). Glycerosomes are formulated 
using glycerol as the edge activator in liposomes, a finding that was first reported in 2013 
(8). Glycerosomes have stronger transdermal permeability than conventional liposomes, 
thereby increasing transdermal drug delivery. In addition, glycerosomes have excellent 
stability and biocompatibility and have been used as a vehicle for transdermal and pulmo-
nary drug delivery (9–12).
In the present study, glycerosomes were used as carriers for the transdermal delivery 
of triptolide. The composition of these glycerosomes was optimized using an orthogonal 
experimental design. The transdermal permeation of triptolide loaded into glycerosomes 
was compared to conventional liposomes.
EXPERIMENTAL
Materials and animals
Triptolide (purity ≥ 98 %) was purchased from Chengdu Pufei De Biotech Co., Ltd. 
(China). Glycerol was obtained from Beijing Dingguo Changsheng Biotech Co., Ltd. (China). 
Soy lecithin (S80, phosphatidylcholine ≥ 80 %) was provided by Tywei Pharmaceutical Co., 
Ltd. (China). All other reagents were obtained from Sinopharm Chemical Reagent Co., Ltd. 
(China).
Fifteen healthy male Sprague Dawley rats, weighing 200 ± 20 g, were provided by the 
Experimental Animal Center of Shanghai University of Traditional Chinese Medicine. The 
animal protocol was approved by the Experimental Animal Ethics Committee of Shanghai 
University of Traditional Chinese Medicine. Animals were kept in an agreeable environ-
ment with free access to rodent diet and water and were acclimatized for 1 week before the 
start of the study.
Analytical method
Triptolide was analyzed using a high-performance liquid chromatography system 







Fig. 1. Chemical structure of triptolide.
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(250 × 4.60 mm, 5 μm) chromatographic column (Dikma Technology, China). The column 
was maintained at 35 °C, the mobile phase composition was methanol/water (60:40, V/V) 
and the flow rate was 1.0 mL min–1. The detection wavelength was 218 nm, as used in a 
previous study (13). The retention time of triptolide was 5.0 min and no chromatographic 
peak appeared at this retention time in the fresh receiving solution (Fig. 2), which did not 
contain the drug, indicating that there was no interference associated with the quantifica-
tion of triptolide. The linear relationship between the area of chromatographic peak and 
triptolide concentration in the receiving solution was good within a concentration range 
of 0.08–5 μg mL–1 (regression equation: y = 31231x – 1522, R2 = 0.9997). The precision and 
accuracy of the method were consistent with the requirements.
Preparation of nanoformulations
Glycerosomes were prepared by the injection method (14). Cholesterol, soy lecithin and 
triptolide, with the final concentrations of 0.167, 5 and 1 mg mL–1 in the glycerosomes, respec-
tively, were dissolved in half the weight of glycerol in the glycerosome formulation and 
mixed using a magnetic stirrer (IKA®RCT, IKA, Germany) at 600 rpm for 1 h, at 40 °C. The 
remaining glycerol was slowly injected and stirring continued for 1 h and the final concen-
tration of glycerol was 20 % (V/V). The size distribution of the glycerosome suspension ini-
tially obtained was reduced by ultrasonication for 10 min (900 Hz; interval time, 3 s) with an 
ultrasonic tissue crusher (SCIENTZ-IID, Ningbo Xinzhi Biotechnology Co., Ltd., China).
For comparison, conventional liposomes were prepared as follows: cholesterol, soy 
lecithin and triptolide, with the same final concentrations as in the glycerosomes, were 
dissolved in 1 mL of ethanol, slowly injected into 10 mL of purified water and mixed using 
a magnetic stirrer at 600 rpm at 50 °C. Thereafter, ethanol was removed by nitrogen sweep-
ing and the dispersion was subjected to ultrasonication for 10 min (900 Hz; interval time, 
3 s) to obtain the final liposome preparation.
The aqueous solution of triptolide glycerol (glycerol solution) was prepared by dis-
solving triptolide (final concentration: 1 mg mL–1) in a 20 % aqueous solution of glycerol 
and vortexing the mixture for 10 min. All prepared samples were stored at 4 °C.
Fig. 2. Chromatograms obtained by high-performance liquid chromatography of: a) triptolide metha-
nol solution, b) fresh receiving solution (without the drug) used for the ex vivo transdermal test and 
c) receiving solution sampled from the triptolide-loaded glycerosomes administered in the ex vivo 
skin permeation experiments. The arrow indicates the chromatographic peak of triptolide.
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Characterization of nanoformulations
The nanopreparations were diluted with distilled water and dropped into a sample 
container. The particle size distribution was determined by dynamic light scattering and 
the zeta potential was measured using a Zetasizer Nano ZS 90 instrument (UK).
The glycerosome dispersion was placed on a copper mesh with a supporting film and 
allowed to dry. Negative staining was performed with 2 % phosphomolybdic acid for 2–3 min 
and the preparation was imaged using a transmission electron microscope (Tecnai G2 
Spirit BioTWIN, USA).
Determination of entrapment efficiency and drug loading
A centrifugal ultrafiltration method was used to determine the entrapment efficiency 
(EE) of the nanocarriers. The nanopreparations were placed in an ultrafiltration centrifuge 
tube (molecular weight cut-off: 100 kDa) and centrifuged at 7853 ×g for 20 min to com-
pletely filter the dispersion medium. The sediment was washed twice with 0.5 mL of water. 
The filtrate was analyzed by HPLC to calculate the free drug content. Equations 1 and 2 

















100 %  (2)
where m0 is the mass of the empty nanocarrier, m1 is the mass of free drug and m2 is the 
total mass of drug in the preparation.
Optimization of glycerosome formulation using orthogonal experimental design
Glycerol concentration (A), phospholipid to cholesterol mass ratio (B) and phospho-
lipid to triptolide mass ratio (C) were set as independent variables (Table I). The weighted 
scores of EE and DL were set as dependent variables. The standard score was 100 points 
and DL and EE accounted for 50 % of each score. The glycerosome formulation was 
 arranged according to a four-factor, three-level orthogonal table [L9 (34)].
Table I. Factor-level arrangement table
Level A (%, V/V) B (m/m) C (m/m)
1 10 10:1 5:1
2 20 20:1 15:1
3 30 30:1 30:1
A – glycerol concentration, B – phospholipid to cholesterol mass ratio, 
C – phospholipid to triptolide mass ratio.
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Preparation stability
The glycerosomes prepared with the selected formulation were stored at 4 °C and the 
EE, zeta potential and size distribution were measured on the day of preparation and after 
30 days of storage.
Ex vivo transdermal experiment
The rats were randomly divided into three groups (glycerosomes, conventional lipo-
somes and aqueous glycerol solution; five animals in each group) and anesthetized with 
ether inhalation. The abdominal hair was carefully shaved with an electric shaver until the 
length of the hair was less than 2 mm; thereafter, the rats were sacrificed. The abdominal 
skin was isolated quickly and the subcutaneous fat and adhering materials were carefully 
removed. The thickness of the final isolated skin was 0.8–1.2 mm. The skin was washed 
with normal saline, its integrity was examined and it was immediately used for the ex vivo 
transdermal test.
A modified vertical Franz transdermal diffusion cell (with an effective diffusion area of 
2.0 cm2 and a receiving cell volume of 12.5 mL; TT-06, Zhengtong Technology Co., Ltd. 
(China) was used for performing the transdermal test. The skin was fixed tightly on the 
donor cell with the stratum corneum facing upward. One mL of the tested triptolide prepa-
ration (triptolide concentration: 1 mg mL–1) was applied evenly to the skin surface. A 20 % 
solution of PEG400 was used as the receiving solution and maintained at 37 °C. A 1 mL ali-
quot was sampled from the receiving cell at 1, 2, 3, 5, 7, 12 and 24 h and an equal volume of 
fresh receiving solution, preheated to 37 °C, was added after sampling. The samples were 
analyzed by HPLC and the cumulative drug penetration per unit area at different time 
points was calculated.
Statistical methods
The experimental data are expressed as mean ± standard deviation. One-way analysis 
of variance was used for comparisons between groups. Statistical analyses were per-
formed using the SPSS 18.0 statistical software and a value of p < 0.05 was considered to 
represent a statistically significant difference.
RESULTS AND DISCUSSION
Optimization of glycerosome formulations
Recently, the superiority of glycerosomes as carriers for transdermal drug administra-
tion has garnered attention from researchers. Glycerosomes have been used to encapsulate 
small-molecule compounds, proteins and even some natural extracts with high EE, such 
as Hypericum scruglii extract and curcumin (15–20).
The composition of the formulation has a major influence on the EE and DL of glycero-
somes (21). To reduce the number of experiments without affecting the results for opti-
mizing the formulation, various experimental design methods, such as orthogonal design, 
uniform design and Box-Behnken design, can be used (22–24). Orthogonal design is the 
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main method of fractional factorial design. When three or more factors are involved with 
potential interactions among the factors, the workload of the experimenter becomes large 
and it might be difficult to execute the experiment. Assuming orthogonality in the ortho-
gonal table, representative points are selected and a result equivalent to that obtained after 
a large number of comprehensive tests can be achieved with a minimum number of tests. 
Thus, the application of the orthogonal design according to an orthogonal table is an 
 efficient, fast and economical multi-factor experimental design method. For example, for a 
three-factor three-level experiment, according to the requirements for a comprehensive 
experiment, 27(33) experimental combinations should be assessed and the number of 
 repetitions for each combination is not considered. If the experiment is arranged according 
to the L9(3) orthogonal table, only nine tests are needed.
Using the L9(34) orthogonal table, the results for the optimization of the glycerosome 
formulation in the present study are listed in Table II. The EE and DL of the glycerosomes 
in each group ranged from 43.25 to 77.40 % and from 3.07 to 16.19 %, respectively. The 
phospholipid to triptolide mass ratio (C) had a significant effect on the experimental re-
sults (Table III). An increase in the phospholipid mass ratio increased the EE of the drug 
and a large amount of carrier material reduced the DL; the weighting value of EE and DL 
decreased as the proportion of phospholipids increased. Similarly, Pleguezuelos-Villa et al. 
reported stable incorporation of mangiferin in glycerosomes at increasing drug concentra-
tions; however, this pattern was not observed for ethanol-formulated ethosomes (10). The 
concentration of glycerol (A) and the phospholipid to cholesterol mass ratio (B) had a smaller 
effect on the experimental results. This is similar to the results obtained in a previous 
Table II. Experimental arrangement and results based on the L9(34) orthogonal table
FN A B C D EE (%) DL (%) WS
1 1 1 1 1 65.67 15.41 90.01
2 1 2 2 2 61.87 5.97 58.41
3 1 3 3 3 55.79 3.12 45.68
4 2 1 2 3 65.56 5.71 60.00
5 2 2 3 1 54.64 3.07 44.78
6 2 3 1 2 77.40 16.19 100.00
7 3 1 3 2 43.25 2.93 37.00
8 3 2 1 3 67.37 15.97 92.84
9 3 3 2 1 54.85 6.06 54.14
K1 64.700 62.337 94.283 62.977
K2 68.260 65.343 57.517 65.137
K3 61.327 66.607 42.487 66.173
Range 69.33 4.270 51.796 3.196
FN – formulation number, EE – entrapment efficiency, DL – drug loading of triptolide, WS – weighted score, A – glycerol 
concentration, B – phospholipid to cholesterol mass ratio, C – phospholipid to triptolide mass ratio, D – error term.
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study, wherein it was reported that the EE of glycerosomes increased only by 1 %, the DL 
remained almost unchanged when the concentration of glycerol was increased from 20 to 
30 % and the phase transition temperature of the corresponding phospholipid membrane 
from a gel state to a liquid crystal state was almost the same (8). Manca et al. also found that 
when the concentration of glycerol was increased from 10 to 20 %, the amount of transdermal 
diclofenac sodium in the total drug content of the tested preparation accumulated over 8 h 
increased from 4.0 to 7.8 %, although it decreased slightly to 7.4 % with a further increase 
in glycerol concentration to 30 % (8). Based on the results of the orthogonal experimental 
design, the following optimal composition was selected for the preparation of glycero-
somes: the concentration of glycerol was 20 %, phospholipid/cholesterol (m/m) was 30:1 and 
phospholipid/triptolide (m/m) was 5:1 (25).
Three batches of glycerosomes were prepared according to the optimal formulation. 
The average particle size was 153.10 ± 2.69 nm, the zeta potential was –45.73 ± 0.60 mV, EE 
was 75.97 ± 0.94 % and DL was 16.15 ± 0.07 %. The average particle size of the comparable 
conventional liposomes was 187.25 ± 11.65 nm, which was larger than that of the glycero-
somes; this was mainly attributable to the high concentration of glycerol in the glycerosomes, 
which increased the fluidity of the phospholipid membrane and resulted in a reduction in 
the particle size (8). Glycerosomes formulated with dipalmitoylphosphatidylcholine are 
slightly larger but more polydisperse than those formulated without glycerol (26). The zeta 
potential of conventional liposomes was –19.32 ± 0.80 mV, which was significantly lower than 
that of the glycerosomes, perhaps owing to the increased negative charge on the surface of 
glycerosomes conferred by glycerol increasing the zeta potential (27, 28). In addition, the 
high concentration of glycerol increased the solubility of insoluble triptolide, allowing the 
drug to be distributed in the bilayer of the huge internal water chamber of glycerosome 
vesicles, thereby resulting in higher EE and DL than those for conventional liposomes, 
which had values of 52.16 ± 1.44 % and 8.75 ± 0.53 %, respectively (29).
Transmission electron microscopy revealed that the glycerosome nanovesicles were 
spherical, uniformly dispersed and did not show aggregation (Fig. 3). The average particle 
size distribution was slightly smaller than that determined by dynamic light scattering. 
This might be because the value determined by dynamic light scattering includes the 
thickness of the outer water film of the phospholipid membrane and the particle size mea-
sured by transmission electron microscopy is based on the morphology of the dried phospho-
lipid vesicles.
Table III. ANOVA results
Factors DEVSQ df F-value CV
A 72.124 2 4.519 19.000
B 28.869 2 1.809 19.000
C 4260.583 2 266.971* 19.000
D (Errors) 15.96 2
DEVSQ – the sum of squares of mean deviation, df – degrees of freedom, CV – critical value of the F-test. 
* Significant difference compared to CV, based on F-test.
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Glycerol increased the viscosity of the glycerosomes, enhancing the stability of the 
nanovesicles (30). After storage at 4 °C for 30 days, the particle size distribution, EE and DL 
of the glycerosomes were not significantly changed (p > 0.05), thus indicating good stability.
Permeation of triptolide in rat skin
Glycerosomes can significantly improve the transdermal delivery of drugs. For example, 
the transdermal flux of diclofenac sodium mediated by glycerosomes containing 20 % 
glycerol was reported to be 1.5-times higher than that obtained using conventional lipo-
somes and glycerosome-enhanced lacidipine permeation by 3.65-fold compared with that 
achieved with lacidipine suspension ex vivo (8, 31). In a previous study, we showed that 
glycerosomes greatly enhanced the transdermal delivery of paeoniflorin, a water-soluble 
active ingredient (32). Herein, we found that the cumulative transdermal amount of trip-
tolide in the glycerosome group over 24 h was 1.78- and 1.52-times higher than those in the 
Fig. 3. Micrograph of triptolide-loaded glycerosomes taken by transmission electron microscope 
( arrows point to glycerosomes).
Fig. 4. The ex vivo permeation-time curves for permeation of triptolide in glycerosomes, conventional 
liposomes and 20 % glycerol solution through the isolated skin of rats over 24 h (**p < 0.01; n = 5).
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conventional liposome group and the triptolide 20 % glycerol solution group, respectively 
(p < 0.01) (Fig. 4). In addition, the transdermal flux in the glycerosome group was signifi-
cantly greater than that in the conventional liposome and glycerol solution groups (p < 
0.05) (Fig. 5). The transdermal permeability in the conventional liposome group was lower 
than that in the glycerol solution group, which indicates that 20 % glycerol had an enhanc-
ing effect on the penetration.
Previous reports have shown that the elasticity of glycerosomes increases with an  increase 
in glycerol content (8). At 30 % glycerol concentration, the deformation index of glycerosomes 
was twice the value of control liposomes, indicating that glycerol could act as an edge activator 
for phospholipid membranes, though only at high concentrations (> 10 %) (33). The incorpo-
ration of certain drugs, such as diclofenac sodium, influences the glycerosome membrane 
and may interfere with membrane deformability (33). In another study, based on small-angle 
X-ray scattering, a strong dose-dependent interaction between glycerol and polar portions 
of phospholipid molecules was observed, whereas encapsulated quercetin did not significantly 
alter bilayer packing (34). In addition to being dispersed in the phospholipid membrane as 
an edge activator, the glycerol present in the internal water compartment increases the loading 
of liposoluble compounds, whereas the glycerol outside the vesicle has a moisturizing and 
penetration enhancing effect, which helps the drug to penetrate the skin. In summary, 
 glycerol contributes to the deformability of glycerosomes and serves as an enhancer of drug 
penetration, concomitantly enhancing the plasticity and hydration of the stratum corneum, 
thereby, resulting in efficient transdermal delivery of drugs (35). In addition, glycerol in the 
glycerosomes forms more viscous systems than those of conventional liposomes, therefore 
improving their spreadability on the skin (36).
CONCLUSIONS
In this study, an orthogonal experimental design was used to optimize the composi-
tion of glycerosome formulations. The prepared glycerosomes significantly enhanced the 
percutaneous delivery of triptolide. Glycerosomes had greater transdermal permeability, 
Fig. 5. Ex vivo transdermal flux of triptolide in glycerosomes, conventional liposomes and 20 % glycerol 
solution (*p < 0.05; n = 5).
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stability and biocompatibility than conventional liposomes. Consequently, glycerosomes 
have great potential as vehicles for dermal and transdermal drug delivery.
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